LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• LifeMD, Inc. has received an average rating of "Moderate Buy" from nine analysts, with a twelve-month price target of $13.17.
• Insider Nicholas P. Alvarez sold 75,000 shares at an average price of $5.92, reducing his ownership by 11.03%.
• Institutional investors have significantly increased their holdings in LifeMD, with Arrowstreet Capital increasing their stake by 1,767.8% in the second quarter.

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.1667.

LFMD has been the subject of several recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of LifeMD in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Lake Street Capital lowered their target price on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. HC Wainwright lowered their price objective on shares of LifeMD from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Zacks Research upgraded shares of LifeMD from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th.

Insider Activity at LifeMD

In other news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the sale, the insider directly owned 605,000 shares in the company, valued at approximately $3,581,600. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 18.40% of the company's stock.

Institutional Investors Weigh In On LifeMD

Several institutional investors and hedge funds have recently made changes to their positions in LFMD. Arrowstreet Capital Limited Partnership lifted its stake in shares of LifeMD by 1,767.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company's stock worth $5,924,000 after buying an additional 411,651 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company's stock worth $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Jump Financial LLC raised its holdings in shares of LifeMD by 205.0% during the second quarter. Jump Financial LLC now owns 515,052 shares of the company's stock worth $7,015,000 after purchasing an additional 346,171 shares during the last quarter. Invesco Ltd. raised its holdings in shares of LifeMD by 1,904.0% during the second quarter. Invesco Ltd. now owns 327,080 shares of the company's stock worth $4,455,000 after purchasing an additional 310,759 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of LifeMD during the first quarter worth $1,545,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Price Performance

Shares of LFMD opened at $6.08 on Friday. The company has a market cap of $288.31 million, a price-to-earnings ratio of -28.95 and a beta of 1.67. LifeMD has a twelve month low of $3.99 and a twelve month high of $15.84. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. The company has a 50 day moving average of $6.36 and a two-hundred day moving average of $8.65.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.